Vogl, NY
RxPonder Changes the Field for Premenopausal Breast Cancer Patients With Involved Nodes
Attention must be paid to this large study that showed a substantial 5-year benefit from adding chemotherapy to the surgery, radiation and standard endocrine therapy given to premenopausal women with 1 to 3 involved axillary nodes and Oncotype Dx recurrence scores less than 26.
FEBRUARY 25, 2021
RxPonder Results for Postmenopausal Women: Skip Chemo With RS <26 and 1 to 3 Positive Nodes
RxPonder is not a noninferiority study showing that we lose very little by skipping chemotherapy for postmenopausal women with 1 to 3 positive axillary nodes and OncotypeDx recurrence score (RS) (Genomic Health, now bought by Exact Sciences) less than 26.
FEBRUARY 25, 2021
Vogl, NY: Adjuvant CDK Inhibitors—Time for Neither Despair Nor Exultation!
ESMO 2020 saw the presentation of early results from 2 double-blind, placebo-controlled trials examining adjuvant hormonal therapy for resected very high–risk, hormone receptor–positive breast cancer with cyclin dependent kinase (CDK) 4/6 inhibitors or placebo.
JANUARY 7, 2021
Vogl, NY: Oral Paclitaxel—Handle with Care and Skepticism
At least 4 reasons exist for clinicians and federal agencies to question the results presented to date.
MAY 18, 2020
12,834 Colon Ca Patients: Wrong Design, Wrong Question!
At the 2017 ASCO annual meeting, Qian Shi, PhD, from Mayo Clinic in Rochester, Minnesota, presented a combined individual-patient analysis of 6 studies conducted around the world, looking at 6 versus 3 months of adjuvant chemotherapy for node-positive colon cancer.
JULY 20, 2017
A Viper Bites Med Literature Again: Guarantee-Time Bias
The February 10, 2017, issue of the Journal of Clinical Oncology (JCO) included a matched propensity score (prognostic factor) analysis of preoperative and postoperative adjuvant chemotherapy for stage I and II pancreatic cancer.
JULY 5, 2017
Vogl, NY: Adjuvant OFS for Resected Breast Cancer Revisited
After the results of the Eastern Cooperative Oncology Group (ECOG) 5188 study (Intergroup 0101) were published by Davidson et al, many of us in the field hoped that a study of additional adjuvant ovarian function suppression (OFS) restricted to women with functioning ovaries would demonstrate clearly the benefit of OFS.
APRIL 29, 2017
Value of Extended Adjuvant AI Therapy Is Still Unclear
At SABCS 2016, investigators reported 3 new studies on extended adjuvant aromatase inhibitors (AIs)—a large American trial (NRG Oncology/NSABP B-42) and 2 relatively small Dutch ones (IDEAL and DATA).
FEBRUARY 13, 2017
Myeloma–Time To Push for a Cure With MRD End Points
It's time for a push toward cure of MM. The best available landmark for such a push is the eradication of any detectable myeloma cells in the bone marrow.
NOVEMBER 2, 2016
Extended Adjuvant AIs: Safe and Active, but Not Much Good
Paul E. Goss, MD, PhD, presented the 6.3-year analysis of the MA.17R breast cancer trial at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO).
SEPTEMBER 19, 2016
Failure To Achieve pCR: Offer Capecitabine for TNBC
S-J Lee presented a groundbreaking Japanese-Korean trial (JBCRG-04 or CREATE-X, [Capecitabine for Residual cancer as Adjuvant ThErapy]) at the 2015 annual meeting of the San Antonio Breast Cancer Symposium seeking to tell oncologists what to do if a patient still has obvious cancer in the breast or nodes after neoadjuvant chemotherapy.
JULY 26, 2016
Vogl, NY: Impaired Quality of Death
Newspapers in July 2015 were filled with reports about second-line chemotherapy impairing the quality of the last week of life for cancer patients.
APRIL 29, 2016
